Login to Your Account

Anthera phase III thrown for a 'lupus,' BAFF last laugh by year's end?

By Randy Osborne
Staff Writer

Thursday, November 10, 2016

Despite sliding past an interim futility analysis in February 2015, Anthera Pharmaceuticals Inc.'s blisibimod couldn't hit the phase III endpoint against SLE in the trial called CHABLIS-SC1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription